BESREMi is a preferred, FDA-approved option for both symptomatic low- and high-risk polycythemia vera patients. In the polycythemia vera space, BESRE ...

The "Myelofibrosis (MF) - Market Insight, Epidemiology, and Market Forecast - 2034" report has been added to ResearchAndMarkets.com's offering. The report delivers an in-depth understanding of the ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

Bristol Myers Squibb announces positive data from POETYK PSO LTE trial of Sotyktu to treat moderate-to-severe plaque psoriasis: Princeton, New Jersey Tuesday, February 18, 2025, 1 ...

such as Novartis and Incyte’s JAK1/2 inhibitor Jakafi (ruxolitinib). Around one-third of them have platelet counts below the threshold that makes the eligible for Vonjo treatment. Analysts said ...

Due to their potent and broad effects on multiple proinflammatory mediators, JAK inhibitors have set a new precedent for therapeutic thresholds. So far, one topical JAK1–2 inhibitor (ruxolitinib), two ...

Tumour cells can escape the therapeutic effects of selective JAK2 inhibitors by mutation-independent transactivation of JAK2 by JAK1. Here, we used selective JAK2 inhibition as a model to test the ...

Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a plasma elimination half-life of 12 hours and has been administered in a twice-daily dosing ...

Bristol Myers Squibb today announced new five-year results from the POETYK PSO long-term extension (LTE) trial of Sotyktu (deucravacitinib) treatment in adult patients with moderate-to-severe plaque ...

Basilea Pharmaceutica may finally be able to bring its antibiotic ceftobiprole to the US market – 13 years after its first attempt was turned down – thanks to a new phase 3 clinical trial.